With a looming crisis of widespread contagion, the FDA announced on August 9 that rather than the prescribed two-shot dosage, the agency has issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection. (Source.)

FDA Announcement.

We saw throughout the COVID Plandemic that the pharmaceutical industry took advantage of "Public Health Emergency" designations to get the FDA to issue EUAs (emergency use authorization) to get new, untested vaccines into the market as soon as possible without proper testing, and more importantly for the pharmaceutical companies, no legal liabilities.

With the W.H.O. and the U.S. Government now declaring monkeypox to be a "Public Health Emergency," could the same thing happen with new vaccines and drugs for monkeypox?

The problem in issuing the existing smallpox/monkeypox vaccine an EUA, is that it was already approved by the FDA, even though it has not been tested in the public much beyond the initial trials conducted by the drug company.

According to Dr. Meryl Nass, that may not stop them from figuring out a way to get the FDA to issue them an EUA to avoid legal liability: